Press Releases

Date	Title and Summary	View
Apr 28, 2020	MacroGenics to Host its Annual Meeting of Stockholders in Virtual Format Rockville, MD , April 28, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that its 2020 Annual Meeting of
Apr 28, 2020	MacroGenics Announces Date of First Quarter 2020 Financial Results Conference Call Rockville, MD , April 28, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its
Apr 27, 2020	MacroGenics Announces Presentation of Flotetuzumab Translational Data at the 2020 AACR Annual Meeting Rockville, MD , April 27, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced data related to flotetuzumab, an
Mar 04, 2020	MacroGenics Announces Departure of Chief Medical Officer Rockville, MD , March 04, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, announced that Jon Wigginton , M.D., Senior Vice
Feb 27, 2020	MacroGenics to Participate in Upcoming Investor Conferences ROCKVILLE, MD , Feb. 27, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will
Feb 25, 2020	MacroGenics Provides Update on Corporate Progress and 2019 Financial Results Margetuximab: BLA for metastatic HER2-positive breast cancer accepted for review by the FDA; Phase 2/3 MAHOGANY study ongoing in front-line advanced HER2-positive gastric cancer First clinical data from Phase 1/2 studies of MGD013, MGC018 and MGD019 anticipated in 2020 Conference call scheduled for
Feb 13, 2020	MacroGenics Announces Date of Fourth Quarter and Full Year 2019 Financial Results Conference Call Rockville, MD , Feb. 13, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its
Feb 10, 2020	MacroGenics to Participate in Upcoming Investor Conferences ROCKVILLE, MD , Feb. 10, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will
Jan 13, 2020	MacroGenics to Present at the J.P. Morgan Healthcare Conference Rockville, MD , Jan. 13, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will present at the
Jan 09, 2020	MacroGenics Outlines Corporate Priorities for 2020 Rockville, MD , Jan. 09, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced its corporate and program priorities
Dec 19, 2019	MacroGenics Announces Submission of Margetuximab Biologics License Application to U.S. FDA ROCKVILLE, MD , Dec. 19, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company has submitted a
Dec 11, 2019	MacroGenics Presents Results from the SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium Biologics License Application (BLA) submission to FDA expected before the end of 2019 Rockville, MD , Dec. 11, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based
Dec 09, 2019	MacroGenics Presents Flotetuzumab Data in Patients with Primary Induction Failure and Early Relapsed Acute Myeloid Leukemia at the 2019 ASH Annual Meeting Conference call scheduled for today at 8:00 p.m. ET Rockville, MD , Dec. 09, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer,
Dec 02, 2019	MacroGenics to Participate in the Evercore ISI HealthCONx Conference Rockville, MD , Dec. 02, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will
Nov 07, 2019	MacroGenics to Participate in Upcoming Investor Conferences Rockville, MD , Nov. 07, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will
Nov 06, 2019	MacroGenics Provides Update on Corporate Progress and Third Quarter 2019 Financial Results Conference call scheduled for today at 4:30 p.m. ET ROCKVILLE, Md. , Nov. 06, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer,
Nov 06, 2019	MacroGenics Announces Flotetuzumab Presentations at the ASH Annual Meeting 2019 ROCKVILLE, MD , Nov. 06, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the clinical and preclinical abstracts
Oct 30, 2019	MacroGenics Announces Date of Third Quarter 2019 Financial Results Conference Call Rockville, MD , Oct. 30, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its
Oct 25, 2019	MacroGenics Announces Initiation of Phase 2/3 MAHOGANY Study of Margetuximab in Gastric or Gastroesophageal Junction Cancer Rockville, MD , Oct. 25, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the first patient has been dosed
Oct 22, 2019	MacroGenics Announces Second Interim Overall Survival Data from Phase 3 SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer ROCKVILLE, MD , Oct. 22, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced topline results from the second
Sep 30, 2019	MacroGenics Presents Margetuximab Data in Gastroesophageal Cancer at the ESMO 2019 Congress ROCKVILLE, MD , Sept. 30, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced updated results from a Phase 2 study
Sep 26, 2019	MacroGenics to Participate in Cantor Global Healthcare Conference ROCKVILLE, MD , Sept. 26, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will
Aug 29, 2019	MacroGenics to Participate in Upcoming Investor Conferences ROCKVILLE, MD , Aug. 29, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will
Aug 08, 2019	MacroGenics to Participate in Upcoming Investor Conferences Rockville, MD , Aug. 08, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will
Jul 31, 2019	MacroGenics Provides Update on Corporate Progress and Second Quarter 2019 Financial Results Conference call scheduled for today at 4:30 p.m. ET ROCKVILLE, Md. , July 31, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer,